Pharmaceuticals - Central America

  • Central America
  • The revenue in the Pharmaceuticals market in Central America is expected to reach US$2,032.00m in 2024.
  • Among the various markets, the largest market is Oncology Drugs, which is projected to have a market volume of US$318.40m in 2024.
  • Furthermore, the revenue in the Pharmaceuticals market is anticipated to exhibit an annual growth rate of 3.84% (CAGR 2024-2029), resulting in a market volume of US$2,453.00m by 2029.
  • In comparison to other countries worldwide, United States is expected to generate the highest revenue, amounting to US$630.30bn in 2024.
  • In Central America, the pharmaceutical market is experiencing a surge in demand for generic drugs due to their affordability and accessibility.

Key regions: United States, China, Germany, Japan, Europe

 
Market
 
Region
 
Region comparison
 
Currency
 

Analyst Opinion

Central America, a region located between North and South America, has seen a steady growth in its pharmaceuticals market over the past few years.

Customer preferences:
One of the primary drivers of this growth is the increasing demand for healthcare services in the region. With a growing population and an increase in the prevalence of chronic diseases, there is a greater need for pharmaceutical products. Additionally, the region's middle class is expanding, and with it, their purchasing power. This has led to a greater demand for higher quality and more expensive medications.

Trends in the market:
Each country in Central America has its own unique pharmaceutical market, with varying trends. For example, in Guatemala, there has been a growing trend towards the use of generic drugs, as they are more affordable for the majority of the population. In contrast, in Costa Rica, there has been a greater demand for branded drugs, as the population has a higher disposable income.

Local special circumstances:
One of the challenges facing the pharmaceutical market in Central America is the lack of regulation and oversight. This has led to a proliferation of counterfeit drugs, which can be dangerous for consumers. Additionally, there is a lack of investment in research and development, which has hindered the development of new and innovative drugs.

Underlying macroeconomic factors:
Despite these challenges, there are several macroeconomic factors that are driving the growth of the pharmaceutical market in Central America. One of these is the increasing investment in healthcare infrastructure by governments in the region. This has led to a greater availability of healthcare services and an increase in demand for pharmaceutical products. Additionally, the region's proximity to the United States has led to an increase in foreign investment, which has helped to stimulate the market. Finally, the region's favorable trade agreements with the United States and other countries have made it an attractive location for pharmaceutical companies looking to expand their operations.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

Overview

  • Revenue
  • Analyst Opinion
  • Global Comparison
  • Methodology
  • Key Market Indicators
Please wait

Contact

Get in touch with us. We are happy to help.
Statista Locations
Contact Meredith Alda
Meredith Alda
Sales Manager– Contact (United States)

Mon - Fri, 9am - 6pm (EST)

Contact Yolanda Mega
Yolanda Mega
Operations Manager– Contact (Asia)

Mon - Fri, 9am - 5pm (SGT)

Contact Ayana Mizuno
Ayana Mizuno
Junior Business Development Manager– Contact (Asia)

Mon - Fri, 10:00am - 6:00pm (JST)

Contact Lodovica Biagi
Lodovica Biagi
Director of Operations– Contact (Europe)

Mon - Fri, 9:30am - 5pm (GMT)

Contact Carolina Dulin
Carolina Dulin
Group Director - LATAM– Contact (Latin America)

Mon - Fri, 9am - 6pm (EST)